Skip to main content

Lessons from TP53mutations in breast cancers: from carcinogen fingerprints to clinical correlates

Full text

About 1000 mutations in breast cancers are listed in the IARC TP53 mutation database [1]. Overall, the mutation prevalence is relatively low (20-30%). Mutations are associated with most aggressive tumor types and carry a significant risk of bad prognosis and outcome in both node-positive and node-negative tumors. Among tumors expressing mutant p53, those with mutations in the L2/L3 loops of the protein (DNA-binding surface) have a poorer response to some forms of treatment than tumors with mutations at other sites [2]. It is noteworthy that p53 protein levels are elevated in more than 50% of breast cancers, suggesting that p53 function may be deregulated by mechanisms other than mutation.

The pattern of TP53 mutations shows a relatively high prevalence of insertions, deletions and nonsense mutations (altogether, 25%). The most frequent mutation type is GC to AT transitions (40%), equally affecting CpG and non-CpG sites. Cohort comparisons have shown differences in the nature, localization and frequency of mutations, but these studies need to be substantiated on larger groups [3].

Breast cancer frequently arises in Li-Fraumeni families [4]. The mutations found in this context may be considered as representative of spontaneous mutations arising in breast cancer. Comparison with sporadic cancer shows that two transversions, G to T and G to C, are not found in Li-Fraumeni breast cancer patients. These transversions represent 18% of somatic breast-cancer mutations. They show a strong strand bias and occur at sites often mutated in lung cancers from smokers (codons 157, 248, 249 and 273) or in bladder cancers from smokers and/or dye-exposed workers (codons 158 and 280). Overall, these data indicate that although most of breast cancer mutations probably have a spontaneous origin, a small proportion of mutations show signatures that suggest the involvement of exogenous carcinogens.

References

  1. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P: . Hum Mutat. 1999, 14: 1-8. 10.1002/(SICI)1098-1004(1999)14:1<1::AID-HUMU1>3.3.CO;2-8.

    CAS  Article  PubMed  Google Scholar 

  2. Aas T, Børresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: . Nature Med. 1996, 2: 811-814. 10.1038/nm0796-811.

    CAS  Article  PubMed  Google Scholar 

  3. Blaszyk H, Hartmann A, Sommer SS, Kovach JS: . Hum Genet. 1996, 97: 543-547. 10.1007/s004390050090.

    CAS  Article  PubMed  Google Scholar 

  4. Ohgaki H, Hernandez T, Kleihues P, Hainaut P: . In Molecular Biology and Cancer Medicine, 2nd Edition, edited by Kurzock R and Talpaz M. Martin Dunitz. 1999, 477-492.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hainaut, P., Olivier, M. Lessons from TP53mutations in breast cancers: from carcinogen fingerprints to clinical correlates. Breast Cancer Res 2, S.21 (2000). https://doi.org/10.1186/bcr140

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/bcr140

Keywords

  • Breast Cancer
  • TP53 Mutation
  • Cohort Comparison
  • Mutation Database
  • Mutation Prevalence